Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
11 evidence topics · 11 sources
Atomoxetine plus racemic oxybutynin, single night: genioglossus responsiveness and AHI (hypopneas with 3% desaturation or arousal)
“ato–oxy lowered AHI by 63% (34–86%), from 28.5 (10.9–51.6) events/h to 7.5 (2.4–18.6) events/h (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1–4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato–oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypopneas were defined as reduction in flow of 30% or more from baseline, lasting at least 10 seconds, and were associated with an arousal from sleep or an oxyhemoglobin desaturation 3% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine plus racemic oxybutynin: effects on endotypic traits
“Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by –9 [–14 to –3]% (P = .022) and LG1 by –11 [–22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine alone versus atomoxetine plus racemic oxybutynin (AD036), home sleep studies (hypopneas with 4% desaturation)
“The apnea–hypopnea index (AHI) from a median (interquartile range) of 14.2 (5.4 to 22.3) events/h on placebo to 6.2 (2.8 to 13.6) with AD036 and 4.8 (1.4 to 11.6) with atomoxetine alone (p < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD036, but not atomoxetine alone, reduced the respiratory arousal index and improved ventilation at the respiratory arousal threshold (greater Vactive). There was a trend for total sleep time to be decreased more with atomoxetine alone than with AD036.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine may account for the majority of improvement in OSA severity, while the addition of oxybutynin may mitigate the disruptive effect of atomoxetine on sleep and further improve ventilation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 4% oxygen desaturation criterion was used for scoring of hypopneas and subsequent calculation of the AHI, and for calculation of the oxygen desaturation index (ODI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of antimuscarinic: atomoxetine with solifenacin or biperiden (AASM scoring)
“Neither drug combination altered the apnea/hypopnea index versus placebo (P = 0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine + biperiden hydrochloride reduces perceived sleepiness, and atomoxetine + solifenacin modestly improves upper airway function in people with OSA but to a lesser extent versus recently published atomoxetine + oxybutynin (broad M-subtype receptor selectivity) findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All overnight in-laboratory sleep studies (polysomnography) were performed according to American Academy of Sleep Medicine guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contribution of the antimuscarinic component to upper airway activity and sleep consolidation
“However, it has become clear, after multiple similar findings, that the SNRIs (atomoxetine or reboxetine) have the most important stimulatory action on the pharyngeal dilator muscles, while the antimuscarinic component has a smaller such effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A second important contribution of the anticholinergic agent in the ato-oxy combination was discovered to be the mitigation of the wake-promoting effects caused by the SNRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oxybutynin was also found to attenuate a reduction in arousal threshold observed with atomoxetine monotherapy, raising the possibility that blocking muscarinic signaling blunts the behavioral/arousal expression of noradrenergic drive48 allowing for HMN activations while maintaining sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AD109 versus atomoxetine alone over 4 weeks: respiratory parameters and total sleep time (MARIPOSA)
“AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AD109 dose response after a single night, APC-004 (hypoxic burden and AHI with 4% desaturation)
Apnea index and hypopnea index (4% desaturation criterion) in the phase 3 trials, on-treatment estimand: company exploratory analysis
REM sleep and body mass index changes in the phase 3 trials
“AD109 was associated with a reduction in REM sleep, consistent with the established effects of noradrenergic, serotonergic, and tryciclic antidepressant agents. The clinical significance of pharmacologically driven REM reduction remains uncertain, and existing evidence suggests that it is not associated with impairments in cognitive performance or vigilance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote